Pfizer Inc (PFE) Q4 2024 Earnings Report

Previous: Q3 2024

Pfizer Inc

PFE

$26.03 1.30%

Exchange: NYSE | Sector: Healthcare | Industry: Drug Manufacturers General

Q4 2024

Published: Feb 27, 2025

Earnings Highlights

Revenue of $17.76B up 19.4% year-over-year
EPS of $0.07 decreased by 86.9% from previous year
Gross margin of 66.7%
Net income of 410.00M
""2024 was a strong year of execution and performance for Pfizer. We were guided by clear strategic priorities...I am pleased with the progress we made in executing transformative changes that strengthen our company." - Albert Bourla" - Albert Bourla

PFE

Pfizer Inc

Period Q4 2024

Currency USD

Report Type Quarterly Earnings

Generated Dec 8, 2025

Executive Summary

Pfizer Inc reported an impressive Q4 2024, achieving $17.8 billion in revenues, representing a 21.9% increase from the previous year. Revenue from non-COVID products rose by 11% year-over-year, with significant contributions from key medications including Vyndaqel, Padcev, and Eliquis. Management expressed optimism regarding a revamped research and development (R&D) approach and the integration of Seagen, intended to enhance market position within oncology. Despite gross margin pressures from COVID-related products and the impact of Medicare pricing reforms, the company maintains a solid profit outlook, reinforced by disciplined capital allocation strategies and ongoing cost reduction efforts.

Key Performance Indicators

Revenue

Increasing

17.76B

QoQ: 0.34% | YoY: 19.38%

Gross Profit

Increasing

11.85B

66.73% margin

QoQ: 6.53% | YoY: 12.92%

Operating Income

Decreasing

3.19B

QoQ: -39.69% | YoY: -30.09%

Net Income

Decreasing

410.00M

QoQ: -90.82% | YoY: -86.84%

EPS

Decreasing

0.07

QoQ: -90.85% | YoY: -86.85%

Revenue Trend

Margin Analysis

Financial Highlights

Revenue: $17.8 billion (+21.9% YoY, +0.34% QoQ)
Gross Profit: $11.85 billion (Gross Profit Margin: 66.7%)
Operating Income: $3.19 billion (Operating Margin: 17.9%)
Net Income: $410 million (Net Margin: 2.3%)
EPS (Diluted): $0.0719
Cash Flow from Operations: $6.55 billion
Debt Ratio: 29.8%
Long-Term Debt to Capitalization: 39.1%
Management noted capital allocation priorities focusing on strengthening R&D investments, targeting a gross leverage of 3.25x by end of 2025, and maintaining dividend commitments to shareholders.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	17.76B	19.38%	0.34%
Gross Profit	11.85B	12.92%	6.53%
Operating Income	3.19B	-30.09%	-39.69%
Net Income	410.00M	-86.84%	-90.82%
EPS	0.07	-86.85%	-90.85%

Key Financial Ratios

Gross Profit Margin

Excellent

66.70%

Gross profit margin is exceptional, indicating strong pricing power and operational efficiency

Operating Profit Margin

Good

17.90%

Operating margin is healthy and competitive within industry standards

Net Profit Margin

Weak

2.31%

Net profit margin is below industry norms, profitability concerns

Return on Assets

Weak

0.19%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

0.47%

Return on equity suggests inefficient capital allocation

Current Ratio

Adequate

1.17

Current ratio meets minimum requirements but limited cushion

Debt to Equity

Elevated

0.72

Debt-to-equity shows significant leverage, monitor debt levels

P/E Ratio

High Growth

94.48x

Very high P/E indicates aggressive growth expectations, higher risk

Price to Book

Fair Value

1.76x

Price-to-book ratio reasonable for profitable companies

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q4 2024	17,763.00	0.07	+19.4%	View
Q3 2024	17,702.00	0.78	+24.2%	View
Q2 2024	13,283.00	0.00	+0.4%	View
Q1 2024	14,879.00	0.55	+16.8%	View

Pfizer Inc (PFE) Q4 2024 Earnings Report

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More PFE Quarterly Reports

PFE

PFE

PFE

Q4 2024 Reports in Healthcare Sector

LLY

Related Financial Data

Sector Analysis: Healthcare

PFE Full Profile

PFE Financial Statements

Earnings Calendar